TerraPower to Build Major Isotope Plant, Tackling Cancer Drug Shortage

PHILADELPHIA, PA – March 17, 2026 – In a move poised to break a critical bottleneck in the development of next-generation cancer treatments, TerraPower Isotopes announced today it will build a flagship manufacturing facility in Philadelphia dedicated to producing actinium-225 (Ac-225), a rare and highly sought-after medical isotope. The new plant, part of a broader expansion, is set to increase the company's production capacity twentyfold, addressing a global shortage that has hampered clinical trials and delayed promising new therapies.

The state-of-the-art facility will be located in Philadelphia's Bellwether District and is slated to begin producing Ac-225 compliant with current Good Manufacturing Practices (cGMP) in 2029. TerraPower Isotopes (TPI), a subsidiary of the nuclear innovation company TerraPower founded by Bill Gates, aims to become the premier global distributor of the isotope, which is a key component in a revolutionary class of treatments known as targeted alpha therapies (TAT).

"TerraPower's mission is to deliver new technologies to market that can improve lives; and the work our TerraPower Isotopes team is doing shows real promise in supporting the expansion of a diverse suite of cancer treatments using nuclear medicine," said TerraPower president and CEO Chris Levesque in a statement. "This new facility will help us increase the global supply of actinium-225 and increase access for researchers and drug developers who are advancing new cancer treatments."

The Race to Cure Cancer's Supply Chain Problem

Actinium-225 is often described by oncologists as a "cancer-seeking missile." When attached to a targeting molecule that homes in on cancer cells, Ac-225 delivers a highly potent, localized dose of alpha particle radiation. This radiation is powerful enough to destroy cancer cells with minimal damage to surrounding healthy tissue, offering a new paradigm in precision medicine. Its 10-day half-life makes it ideal for therapeutic use, providing a sustained attack on tumors before decaying into harmless byproducts.

Despite its immense potential, the advancement of Ac-225-based therapies has been severely constrained by one simple fact: its extreme scarcity. The global supply of Ac-225, which must be artificially produced, is currently estimated to be sufficient to treat only a few thousand patients annually. This bottleneck has created a high-stakes race among pharmaceutical companies to secure a stable supply. In recent years, major players like Bristol Myers Squibb and RayzeBio have been forced to pause or halt enrollment in late-stage clinical trials due to the unavailability of the isotope, delaying potential breakthroughs for patients with neuroendocrine, prostate, and other cancers.

TPI's planned twentyfold production increase represents a direct assault on this supply chain crisis. The move is seen by industry observers as a critical step toward unlocking the full potential of targeted alpha therapies.

"Today marks a major milestone for TerraPower Isotopes and for the future of precision medicine. This new facility is a testament to the demand for actinium-225 as part of the growing industry which is transforming how cancer is treated," said Scott Claunch, president of TerraPower Isotopes. The Philadelphia facility, he added, "will play a pivotal role in expanding global access to this rare isotope."

Philadelphia's New Frontier in Nuclear Medicine

The selection of Philadelphia's Bellwether District for the $450 million project was the result of a rigorous nationwide search that evaluated over 350 potential locations. The 1,300-acre site, a redevelopment of the former Philadelphia Energy Solutions refinery, is being transformed into a hub for logistics, e-commerce, and life sciences, symbolizing the region's shift from old-line industry to a high-tech future.

Pennsylvania is backing the project with $10 million in grants, and the facility is expected to create 225 full-time jobs over the next three years. The decision highlights Philadelphia's growing reputation as a premier center for advanced therapies, boasting a rich ecosystem of research institutions, a skilled workforce, and critical infrastructure.

"TerraPower Isotopes' presence in Philadelphia will strengthen a place where health, science, and technology converge to address some of the world's most pressing challenges," said Kevin B. Mahoney, Chief Executive Officer of the University of Pennsylvania Health System. "The city has a long history of turning ideas and discoveries into advances that accelerate progress, and TerraPower Isotopes' arrival brings new expertise and momentum to the region's dynamic research community."

This sentiment was echoed by others in the local life sciences community. "Philadelphia continues to solidify its position as a premier hub for advanced therapies," noted Sumit Verma, Co-founder of Orchestra Life Sciences. "By establishing a presence here, the TPI team will benefit from a highly collaborative ecosystem that will meaningfully support the company's growth trajectory."

A High-Stakes Nuclear Gambit

While TPI's announcement is a significant development, the company is entering a competitive and technically challenging field. Other firms, such as Wisconsin-based NorthStar Medical Radioisotopes and Germany's ITM Isotope Technologies Munich, are also aggressively scaling up their own Ac-225 production capabilities using different methods, including electron accelerators.

The path from construction to commercial supply is long and fraught with regulatory hurdles. The new facility must meet the FDA's stringent cGMP standards for radiopharmaceuticals, which govern everything from facility design and environmental controls to the handling of radioactive materials and sterility assurance. The short half-life of Ac-225 adds another layer of complexity, demanding a highly efficient and reliable production and logistics chain to ensure the isotope reaches clinical sites and patients on time.

Industry partners, however, view the investment in infrastructure as essential for the entire field to move forward. "TPI's Actinium-225 is already enabling clinical programs around the world as a key component of next-generation targeted alpha therapies," commented Jaap Duiker, Managing Director at Von Gahlen, a supplier of shielding solutions for nuclear medicine. "This new facility represents a critical step in expanding and strengthening the infrastructure required to accelerate the transformation of cancer treatments."

Beyond Energy: The TerraPower Vision

The move into large-scale medical isotope production marks a significant expansion of TerraPower's mission. Founded in 2008 by Bill Gates and a group of like-minded visionaries, the company is best known for its work on advanced nuclear reactors designed to provide safe, affordable, and carbon-free energy. With over $1 billion raised from private investors, including a recent $650 million funding round, and an additional $2 billion in support from the U.S. Department of Energy for its reactor projects, TerraPower has positioned itself as a leader in nuclear innovation.

The TPI subsidiary demonstrates a broader vision where nuclear science is leveraged not only for power generation but also for profound advancements in human health. By tackling the Ac-225 shortage, TerraPower is applying its expertise in nuclear materials and engineering to solve a problem that has held back a promising new frontier in medicine. This strategic diversification underscores the company's commitment to tackling some of the world's most difficult challenges, from climate change to cancer.

This project bridges the gap between the company's energy goals and its potential for direct human health impact, aiming to build a secure supply chain for one of modern medicine's most promising tools in the fight against cancer.